Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Hedvig Vekony"'
Autor:
Robert T. Jones, Andrew Goodspeed, Saswat Mohapatra, Lily Elizabeth Feldman, Mathijs Scholtes, Hedvig Vekony, Annie Jean, Charlene B. Tilton, Michael V. Orman, Cailin Deiter, Nathaniel Xander, Stephanie Araki, Molishree Joshi, Mahmood Javaid, Eric T. Clambey, Ryan Layer, Teemu D. Laajala, Sarah Parker, Tahlita Zuiverloon, Dan Theodorescu, James C. Costello
Despite routine platinum-based chemotherapeutic use in cancer treatment, there remains a need to improve efficacy and patient selection. Using multi-omic assessment of cisplatin responsive and resistant human bladder cancer cell lines and whole-genom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83a8758e02f98a7d486b5a2a7802c45e
https://doi.org/10.1101/2021.03.04.433676
https://doi.org/10.1101/2021.03.04.433676
Autor:
Megan Tu, Emanuel F. Petricoin, James C. Costello, Hedvig Vekony, Annie Jean, Julia D. Wulfkuhle, Dan Theodorescu, Molishree Joshi, Andrew Goodspeed, Teemu D. Laajala, Robert T. Jones, Tahlita C.M. Zuiverloon, Colin Sempeck
Publikováno v:
Cancer Research. 80:4091-4091
Gemcitabine and cisplatin (GC) combination neoadjuvant chemotherapy (NAC) is standard of care for patients with muscle-invasive bladder cancer (MIBC). This combination is preferred due to its favorable toxicity profile. Approximately 25% of NAC treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::220998142a7df0a4ff65100f8a081b47
https://doi.org/10.1158/1538-7445.am2020-4091
https://doi.org/10.1158/1538-7445.am2020-4091
Autor:
Robert T. Jones, Hedvig Vekony, Colin Sempeck, Megan Tu, Tahlita C.M. Zuiverloon, Emanuel F. Petricoin, Teemu D. Laajala, Annie Jean, Molishree Joshi, James C. Costello, Julia D. Wulfkuhle, Dan Theodorescu, Andrew Goodspeed
Publikováno v:
Clinical Cancer Research. 26:B11-B11
Neoadjuvant platinum-based chemotherapy (NAC) followed by radical cystectomy is the preferred first-line option for treating patients diagnosed with muscle-invasive bladder cancer (MIBC). One of the two most commonly utilized chemotherapy regimens fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::170fe6f1e60f8c40f3043f31d043ea97
https://doi.org/10.1158/1557-3265.bladder19-b11
https://doi.org/10.1158/1557-3265.bladder19-b11
Autor:
Robert T. Jones, Tahlita C. Zuiverloon, Hedvig Vekony, Andrew Goodspeed, Teemu D. Laajala, Molishree Joshi, Colin Sempeck, Megan Tu, James C. Costello, Dan Theodorescu
Publikováno v:
Cancer Research. 79:2107-2107
Gemcitabine and cisplatin (GC) combination neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is the standard of care for treating muscle-invasive bladder cancer (MIBC). Approximately 25% of patients experience complete pathologic res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::998c73f13905ff137b5e30925fe65571
https://doi.org/10.1158/1538-7445.am2019-2107
https://doi.org/10.1158/1538-7445.am2019-2107
Autor:
Annemieke J.M. Nieuweboer, Ellen C. Zwarthoff, Hedvig Vekony, Wim J. Kirkels, Tahlita C.M. Zuiverloon, Chris H. Bangma
Publikováno v:
European Urology, 61(1), 128-145. Elsevier
Context: Currently, bacillus Calmette-Guerin (BCG) intravesical instillations are standard treatment for patients with high-grade non-muscle-invasive bladder cancer; however, no markers are available to predict BCG response. Objective: To review the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a44c53805bb80e970715ad471c032191
https://doi.org/10.1016/j.eururo.2011.09.026
https://doi.org/10.1016/j.eururo.2011.09.026